2024-519470-39-00招募中4 期
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fasting Conditions.
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Studies Department
Scientific
Institut De Recherches Internationales Servier IRIS
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.2024-519250-37-00Institut De Recherches Internationales Servier IRIS36
招募中
4 期
Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.2024-519567-18-00Institut De Recherches Internationales Servier IRIS36
招募中
Unknown
Bioequivalence study of Gliclazide 80 mg mgIRCT20220111053692N16Tehran Chemie Pharmaceutical Company24
进行中（未招募）
1 期
Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an a-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients.A 5 to 8 months, national, multicentre, open study.Efficacité et tolérance du gliclazide LM (30 à 120 mg/j per os) associé ou non à la metformine ou à un inhibiteur des a-glucosidases pendant le jeûne du Ramadan chez des patients diabétiques de type 2. Etude nationale, multicentrique de 5 à 8 mois de traitement en ouvert.Diabetes mellitus non insulino dependantMedDRA version: 9.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersEUCTR2006-006754-10-FRInstitut de Recherches Internationales Servier
已完成
1 期
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy AdultsNCT07261371Pfizer64